UTHR Stock: Price, Earnings History and SEC Filings
United Therapeutics Corporation (UTHR) last traded at $598.72, up 0.87% on the latest session and up 10.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $7.27 against an analyst estimate of $6.82, a beat of 6.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
UTHR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $7.27 | $6.82 | +6.60% |
| Mar 2026 | May 6, 2026 | $5.82 | $6.73 | -13.52% |
| Dec 2025 | Feb 25, 2026 | $7.70 | $6.78 | +13.57% |
| Sep 2025 | Oct 29, 2025 | $7.16 | $6.89 | +3.92% |
UTHR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How UTHR reacts to earnings
Across its last 8 earnings releases, UTHR moved 5.8% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +0.06% |
| 2026-05-06 | Before open | +4.29% |
| 2026-02-25 | Before open | +13.03% |
| 2025-10-29 | Before open | +9.63% |
| 2025-07-30 | Before open | -5.25% |
| 2025-04-30 | Before open | +0.77% |
| 2025-02-26 | Before open | -10.80% |
| 2024-10-30 | Before open | +2.44% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
UTHR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $3.2B | $1.3B | $1.0B | 41.9% | $27.86 |
| 2024 | $2.9B | $1.2B | $1.1B | 41.5% | $24.64 |
| 2023 | $2.3B | $985M | $748M | 42.3% | $19.81 |
| 2022 | $1.9B | $727M | $664M | 37.6% | $15.00 |
| 2021 | $1.7B | $476M | $477M | 28.2% | $10.06 |
| 2020 | $1.5B | – | $696M | – | $11.54 |
| 2019 | $1.4B | – | -$290M | – | $-2.39 |
| 2018 | $1.6B | – | $594M | – | $13.39 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for UTHR
- 8-K · Oct 22, 2026Other events, Financial statements and exhibits
- 8-K · Oct 14, 2026Other events, Financial statements and exhibits
- 8-K · Sep 8, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Jul 23, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 29, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 6, 2026
- DEF 14A · Apr 29, 2026
Insider filing activity
UTHR insiders filed 70 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
UTHR news
- SGIOY vs. UTHR: Which Stock Is the Better Value Option?Oct 30, 2026 · finance.yahoo.com
- OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesOct 30, 2026 · finance.yahoo.com
- Why Did Insmed Stock Jump?Oct 30, 2026 · trefis.com
- United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension TherapyOct 29, 2026 · finance.yahoo.com
- Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”Oct 29, 2026 · tikr.com
- Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineOct 29, 2026 · finance.yahoo.com
- United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH TreatmentOct 28, 2026 · investorshub.advfn.com
- Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?Oct 28, 2026 · finance.yahoo.com
About United Therapeutics Corporation
United Therapeutics Corporation (UTHR) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.